Julio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).
Julio Chavez, MD
Advertisement
Articles by Julio Chavez, MD
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia.
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia.
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the ongoing efficacy but also challenges with ibrutinib (Imbruvica) as treatment for patients with chronic lymphocytic leukemia (CLL).
Advertisement
Latest Updated Articles
Dr. Chavez on Ongoing Efficacy and Challenges With Ibrutinib in CLLPublished: August 1st 2017 | Updated:
Dr. Chavez Discusses Ibrutinib Plus Venetoclax in CLLPublished: August 14th 2017 | Updated:
Dr. Chavez Shares His Advice for Treating Patients With CLLPublished: August 16th 2017 | Updated:
Dr. Chavez on Combination of Ibrutinib Plus Ublituximab in CLLPublished: September 7th 2017 | Updated:
- Dr. Chavez on Blinatumomab in ALL
Published: September 7th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5